Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis

OBJECTIVES: In patients with RA treated with (ultra-)low-dose rituximab (RTX), we investigated the association of dosing and timing of RTX on seroconversion after a third coronavirus disease 2019 (COVID-19) vaccination and the persistence of humoral response after a two-dose vaccination. MATERIAL AN...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Togt, Céleste J T, Ten Cate, David F, van den Bemt, Bart J F, Rahamat-Langendoen, Janette, den Broeder, Nathan, den Broeder, Alfons A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452149/
https://www.ncbi.nlm.nih.gov/pubmed/36000861
http://dx.doi.org/10.1093/rheumatology/keac486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452149/
https://www.ncbi.nlm.nih.gov/pubmed/36000861
http://dx.doi.org/10.1093/rheumatology/keac486

Ejemplares similares